Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer

KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), and drive their poor outcomes and failure to respond to targeted therapies. Here we show that Leukemia Inhibitory Factor (LIF) expression is induced specifically by oncogenic KRAS in PDAC and that LIF depletion by ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Man-Tzu, Fer, Nicole, Galeas, Jacqueline, Collisson, Eric A., Kim, Sung Eun, Sharib, Jeremy, McCormick, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624260/
https://www.ncbi.nlm.nih.gov/pubmed/31296870
http://dx.doi.org/10.1038/s41467-019-11044-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624260/
https://www.ncbi.nlm.nih.gov/pubmed/31296870
http://dx.doi.org/10.1038/s41467-019-11044-9

Ejemplares similares